Cargando…

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

PURPOSE: Daunorubicin can induce left ventricular dysfunction and QT interval prolongation. This study assessed the effects of CPX-351, a liposomal encapsulation of cytarabine and daunorubicin, on cardiac repolarization. METHODS: Twenty-six adults with acute leukemia were treated with CPX-351 for 1–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Tara L., Newell, Laura F., Stuart, Robert K., Michaelis, Laura C., Rubenstein, Eric, Pentikis, Helen S., Callahan, Timothy, Alvarez, Donna, Liboiron, Barry D., Mayer, Lawrence D., Wang, Qi, Banerjee, Kamalika, Louie, Arthur C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562048/ https://www.ncbi.nlm.nih.gov/pubmed/31098682 http://dx.doi.org/10.1007/s00280-019-03856-9

Ejemplares similares

Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
por: Wang, Qi, et al.
Publicado: (2018)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML
por: Uy, Geoffrey L., et al.
Publicado: (2022)

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML
por: Molica, Matteo, et al.
Publicado: (2022)

Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo
por: Vincelette, Nicole D., et al.
Publicado: (2019)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
por: Mitchell, Joshua D., et al.
Publicado: (2023)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
por: Rautenberg, Christina, et al.
Publicado: (2021)

CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
por: Urbantat, Ruth M., et al.
Publicado: (2021)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
por: Fortin, Marie C., et al.
Publicado: (2023)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

Successful Treatment of Acute Myeloid Leukemia with CPX-351 in 2 Patients in the United Kingdom during the COVID-19 Pandemic
por: Munisamy, Sreetharan, et al.
Publicado: (2021)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY
por: Ritchie, Ellen, et al.
Publicado: (2023)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
por: Araie, Hiroaki, et al.
Publicado: (2023)

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
por: Fianchi, Luana, et al.
Publicado: (2023)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.
por: Newell, D. R.
Publicado: (1990)

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
por: Guolo, Fabio, et al.
Publicado: (2020)

Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
por: Bernal, Teresa, et al.
Publicado: (2023)

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
por: Cortes, Jorge E., et al.
Publicado: (2021)

PB1879: EFFICACY AND SAFETY OF CPX-351 COMPARED TO STANDARD OF CARE CHEMOTHERAPY IN A REAL-LIFE SETTING: SUPPORTING PREVIOUS EVIDENCE AND FACING NEW CHALLENGES
por: Manghisi, Beatrice, et al.
Publicado: (2023)

Interactions of the CpxA sensor kinase and cognate CpxR response regulator from Yersinia pseudotuberculosis
por: Thanikkal, Edvin J, et al.
Publicado: (2012)

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
por: Luca Morelli, Gian, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
por: Weerink, Maud A. S., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

The two-component system CpxA/CpxR is critical for full virulence in Actinobacillus pleuropneumoniae
por: Liu, Feng, et al.
Publicado: (2022)

Memorandum 351
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1983)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

The CpxA/CpxR Two-Component System Affects Biofilm Formation and Virulence in Actinobacillus pleuropneumoniae
por: Li, Huan, et al.
Publicado: (2018)

The Virulence Effect of CpxRA in Citrobacter rodentium Is Independent of the Auxiliary Proteins NlpE and CpxP
por: Giannakopoulou, Natalia, et al.
Publicado: (2018)

The CpxA/CpxR two-component system mediates regulation of Actinobacillus pleuropneumoniae cold growth
por: Yao, Qing, et al.
Publicado: (2022)

P486: REAL-WORLD EFFECTIVENESS AND SAFETY OF CPX-351 IN PATIENTS AGED <60 AND ≥60 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: CREST-UK POST-HOC ANALYSIS
por: Mehta, Priyanka, et al.
Publicado: (2023)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial
por: Cortes, Jorge E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a98tvjsk4q81vjngvq352usogk